Journal of Clinical Oncology, Vol 12, 1323-1334, Copyright © 1994 by American Society of Clinical Oncology
Treatment of hepatocellular carcinoma: too many options?
AP Venook
Division of Hematology/Oncology, University of California, San Francisco 94143.
PURPOSE: This study attempts to review the therapeutic interventions being
used to treat patients with hepatocellular carcinoma (HCC). DESIGN: An
English language literature search, including abstracts and original
articles, and a review of the bibliographies of such articles, was
conducted. RESULTS: Surgery is possible in few patients and curative in
only a small percentage. Conventional chemotherapy is ineffective in HCC.
Modifications of chemotherapy, including intraarterial infusion,
chemoembolization, lipiodol, styrene-maleic acid-neocarzinostatin (SMANCS),
and isolated hepatic perfusion, have led to improved tumor responses, but
have not materially affected patient outcome. Radioimmunotherapy and
conformal radiotherapy have had no more than a marginal impact on patient
outcome. Surgical innovations such as cryosurgery and percutaneous alcohol
injection have not yet been shown to offer any advantage, and liver
transplantation, while curative in some patients, requires an enormous
expenditure of resources to achieve cure in few patients. CONCLUSION:
Prevention is the ideal approach to HCC. Surgical cure is rarely possible,
and while numerous therapies may palliate symptoms, patient selection and
the lack of randomized studies make their impact on median survival
difficult to assess. Patients being treated for HCC should be enrolled on
treatment protocols testing multimodality or new strategies.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. YEN, S. SO, M. ROSE, M. W. SAIF, E. CHU, S.-H. LIU, A. FOO, Z. JIANG, T. SU, and Y.-C. CHENG
Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma
Anticancer Res,
October 1, 2009;
29(10):
4083 - 4092.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tsuchiyama, Y. Nakamoto, Y. Sakai, Y. Marukawa, M. Kitahara, N. Mukaida, and S. Kaneko
Prolonged, NK Cell-Mediated Antitumor Effects of Suicide Gene Therapy Combined with Monocyte Chemoattractant Protein-1 against Hepatocellular Carcinoma
J. Immunol.,
January 1, 2007;
178(1):
574 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Ben-Josef, D. Normolle, W. D. Ensminger, S. Walker, D. Tatro, R. K. Ten Haken, J. Knol, L. A. Dawson, C. Pan, and T. S. Lawrence
Phase II Trial of High-Dose Conformal Radiation Therapy With Concurrent Hepatic Artery Floxuridine for Unresectable Intrahepatic Malignancies
J. Clin. Oncol.,
December 1, 2005;
23(34):
8739 - 8747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Zhang and P. K. H. Chow
The Effect of Megestrol Acetate on Growth of HepG2 Cells In vitro and In vivo
Clin. Cancer Res.,
August 1, 2004;
10(15):
5226 - 5232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Coradini, S. Zorzet, R. Rossin, I. Scarlata, C. Pellizzaro, C. Turrin, M. Bello, S. Cantoni, A. Speranza, G. Sava, et al.
Inhibition of Hepatocellular Carcinomas in vitro and Hepatic Metastases in vivo in Mice by the Histone Deacetylase Inhibitor HA-But
Clin. Cancer Res.,
July 15, 2004;
10(14):
4822 - 4830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Butterfield, A. Ribas, W. S. Meng, V. B. Dissette, S. Amarnani, H. T. Vu, E. Seja, K. Todd, J. A. Glaspy, W. H. McBride, et al.
T-Cell Responses to HLA-A*0201 Immunodominant Peptides Derived from {alpha}-Fetoprotein in Patients with Hepatocellular Cancer
Clin. Cancer Res.,
December 1, 2003;
9(16):
5902 - 5908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-P. Lee, D.-I. Tai, S.-L. Tsai, C.-T. Yeh, Y. Chao, S.-D. Lee, and M.-C. Hung
Adenovirus Type 5 E1A Sensitizes Hepatocellular Carcinoma Cells to Gemcitabine
Cancer Res.,
October 1, 2003;
63(19):
6229 - 6236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Stuart
Chemoembolization in the Management of Liver Tumors
Oncologist,
October 1, 2003;
8(5):
425 - 437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Sano, T. Takayama, K. Murakami, I. Saiki, and M. Makuuchi
Overexpression of Retinoic Acid Receptor {alpha} in Hepatocellular Carcinoma
Clin. Cancer Res.,
September 1, 2003;
9(10):
3679 - 3683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-L. Liu, S.-T. Fan, C.-M. Lo, I. O.-L. Ng, R. T.-P. Poon, and J. Wong
Hepatic Resection for Bilobar Hepatocellular Carcinoma: Is It Justified?
Arch Surg,
January 1, 2003;
138(1):
100 - 104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-F. H. Geschwind, Y. H. Ko, M. S. Torbenson, C. Magee, and P. L. Pedersen
Novel Therapy for Liver Cancer: Direct Intraarterial Injection of a Potent Inhibitor of ATP Production
Cancer Res.,
July 15, 2002;
62(14):
3909 - 3913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Czauderna, G. Mackinlay, G. Perilongo, J. Brown, E. Shafford, D. Aronson, J. Pritchard, P. Chapchap, J. Keeling, J. Plaschkes, et al.
Hepatocellular Carcinoma in Children: Results of the First Prospective Study of the International Society of Pediatric Oncology Group
J. Clin. Oncol.,
June 15, 2002;
20(12):
2798 - 2804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Benson III, E. Mitchell, N. Abramson, B. Klencke, P. Ritch, J. P. Burnham, C. McGuirt, T. Bonny, J. Levin, and J. Hohneker
Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma
Ann. Onc.,
April 1, 2002;
13(4):
576 - 581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, D.-C. Yu, Y. Chen, P. Amin, H. Zhang, N. Nguyen, and D. R. Henderson
A Hepatocellular Carcinoma-specific Adenovirus Variant, CV890, Eliminates Distant Human Liver Tumors in Combination with Doxorubicin
Cancer Res.,
September 1, 2001;
61(17):
6428 - 6436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tamura, T. Kato, M. Berho, E. P. Misiakos, C. O'Brien, K. R. Reddy, J. R. Nery, G. W. Burke, E. R. Schiff, J. Miller, et al.
Impact of Histological Grade of Hepatocellular Carcinoma on the Outcome of Liver Transplantation
Arch Surg,
January 1, 2001;
136(1):
25 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Dawson, C. J. McGinn, D. Normolle, R. K. Ten Haken, S. Walker, W. Ensminger, and T. S. Lawrence
Escalated Focal Liver Radiation and Concurrent Hepatic Artery Fluorodeoxyuridine for Unresectable Intrahepatic Malignancies
J. Clin. Oncol.,
June 11, 2000;
18(11):
2210 - 2218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Vollmer, A. Ribas, L. H. Butterfield, V. B. Dissette, K. J. Andrews, F. C. Eilber, L. D. Montejo, A. Y. Chen, B. Hu, J. A. Glaspy, et al.
p53 Selective and Nonselective Replication of an E1B-deleted Adenovirus in Hepatocellular Carcinoma
Cancer Res.,
September 1, 1999;
59(17):
4369 - 4374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Torzilli, M. Makuuchi, K. Inoue, T. Takayama, Y. Sakamoto, Y. Sugawara, K. Kubota, and A. Zucchi
No-Mortality Liver Resection for Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients: Is There a Way? A Prospective Analysis of Our Approach
Arch Surg,
September 1, 1999;
134(9):
984 - 992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Wren, M. M. Coburn, M. Tan, J. R. Daniels, N. Yassa, C. L. Carpenter, and S. C. Stain
Is Cryosurgical Ablation Appropriate for Treating Hepatocellular Cancer?
Arch Surg,
June 1, 1997;
132(6):
599 - 604.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. Levin and C. Amos
Therapy of Unresectable Hepatocellular Carcinoma
N. Engl. J. Med.,
May 11, 1995;
332(19):
1294 - 1296.
[Full Text]
|
|
|
|
